# Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

> **NCT06711471** · PHASE2 · RECRUITING · sponsor: **LIN YANG** · enrollment: 31 (estimated)

## Conditions studied

- Gastric Cancer Adenocarcinoma Metastatic

## Interventions

- **DRUG:** trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab

## Key facts

- **NCT ID:** NCT06711471
- **Lead sponsor:** LIN YANG
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-14
- **Primary completion:** 2026-11-13
- **Final completion:** 2027-11-13
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711471, "Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06711471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*